PL366940A1 - Kompleks inkluzyjny s-omeprazolu (esomeprazolu) zcyklodekstrynami - Google Patents

Kompleks inkluzyjny s-omeprazolu (esomeprazolu) zcyklodekstrynami

Info

Publication number
PL366940A1
PL366940A1 PL02366940A PL36694002A PL366940A1 PL 366940 A1 PL366940 A1 PL 366940A1 PL 02366940 A PL02366940 A PL 02366940A PL 36694002 A PL36694002 A PL 36694002A PL 366940 A1 PL366940 A1 PL 366940A1
Authority
PL
Poland
Prior art keywords
omeprazole
esomeprazole
cyclodextrins
inclusion complex
cyclodextrin
Prior art date
Application number
PL02366940A
Other languages
English (en)
Inventor
Yusuf Khwaja Hamied
Dharmaraj Ramachandra Rao
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of PL366940A1 publication Critical patent/PL366940A1/pl

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
PL02366940A 2001-06-06 2002-06-06 Kompleks inkluzyjny s-omeprazolu (esomeprazolu) zcyklodekstrynami PL366940A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex

Publications (1)

Publication Number Publication Date
PL366940A1 true PL366940A1 (pl) 2005-02-07

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366940A PL366940A1 (pl) 2001-06-06 2002-06-06 Kompleks inkluzyjny s-omeprazolu (esomeprazolu) zcyklodekstrynami

Country Status (17)

Country Link
US (1) US20040147481A1 (pl)
EP (1) EP1401442B1 (pl)
JP (1) JP2004536810A (pl)
AT (1) ATE282412T1 (pl)
AU (1) AU2002344386B2 (pl)
CA (1) CA2449769C (pl)
DE (1) DE60201995T2 (pl)
ES (1) ES2232780T3 (pl)
GB (1) GB2376231A (pl)
LT (1) LT5182B (pl)
LV (1) LV13154B (pl)
NZ (1) NZ529956A (pl)
PL (1) PL366940A1 (pl)
PT (1) PT1401442E (pl)
RU (1) RU2313343C2 (pl)
WO (1) WO2002098423A1 (pl)
ZA (1) ZA200309841B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 s-오메프라졸 함유 포접 복합체 및이의 제조방법
DE602006006352D1 (de) * 2005-12-28 2009-05-28 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
WO2009040825A1 (en) 2007-09-25 2009-04-02 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (pl) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CN1113649C (zh) * 1997-03-13 2003-07-09 赫克萨尔股份公司 用氨基酸/环糊精组合稳定酸敏苯并咪唑
ES2149750T3 (es) * 1999-01-06 2004-06-01 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos.
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
DE60023154T2 (de) * 1999-08-26 2006-06-22 Aaipharma Inc. Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
DE60201995D1 (de) 2004-12-23
EP1401442A1 (en) 2004-03-31
ATE282412T1 (de) 2004-12-15
JP2004536810A (ja) 2004-12-09
GB2376231A (en) 2002-12-11
WO2002098423A1 (en) 2002-12-12
PT1401442E (pt) 2005-02-28
DE60201995T2 (de) 2005-11-24
ZA200309841B (en) 2005-03-14
CA2449769C (en) 2010-12-14
AU2002344386B2 (en) 2006-11-30
RU2003137221A (ru) 2005-06-10
LV13154B (en) 2004-07-20
LT2003100A (en) 2004-09-27
GB0113792D0 (en) 2001-07-25
NZ529956A (en) 2005-07-29
ES2232780T3 (es) 2005-06-01
EP1401442B1 (en) 2004-11-17
LT5182B (lt) 2004-12-27
CA2449769A1 (en) 2002-12-12
US20040147481A1 (en) 2004-07-29
RU2313343C2 (ru) 2007-12-27
HK1064602A1 (en) 2005-02-04

Similar Documents

Publication Publication Date Title
AR033096A1 (es) Acomposicion antifungal con aumentada biodisponibilidad
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
EP1374679A3 (en) Sterilizing composition and method for sterilizing using the same
WO2003057135A3 (en) Aqueous compositions containing metronidazole
MXPA03011006A (es) Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
PL366940A1 (pl) Kompleks inkluzyjny s-omeprazolu (esomeprazolu) zcyklodekstrynami
NZ514236A (en) Composition comprising optionally substituted cyclopropene encapsulated in a molecular encapsulation agent (e.g. cyclodextrin), and a water absorbent material
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
EE05402B1 (et) Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks
ATE468843T1 (de) Herstellungsverfahren für wirkstoffträgerteilchen
PE20070378A1 (es) FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA
AR041639A1 (es) Metodo para la sintesis de un compuesto de bencimidazol
TW200730667A (en) Palladium selective etching solution and method of controlling etching selectivity
AU2001293856A1 (en) A process for the preparation of pantoprazole and intermediates therefor
NO20041671L (no) Anthelmintic composition
PT1244643E (pt) Inibidores da triptase
DK1244614T3 (da) Tryptase-inhibitorer
AU2003221507A1 (en) Composition containing organopolysiloxanes, method for the production thereof and use of the same
DE60334929D1 (de) Algainassb-ätzung
JO2240B1 (en) Method for preparing dithylidene derivatives
EA200400382A1 (ru) Применение специфической дозы фондапаринукса натрия для лечения окс
WO2002040032A3 (en) Cytoprotective estrogen derivatives
ES2178618T3 (es) Procedimiento de preparacion del epoxiciclododecadieno.
CO5560539A2 (es) Derivados de 2-hidroxi-2-metil-3,3,3-trifluoropropanamida n-fenilo sustituida que elevan la actividad de piruvato deshidrogenasa
EP1374899A8 (en) Remedies for post-traumatic stress disorder

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)